JP5937586B2 - 分子間相互作用の検出方法 - Google Patents
分子間相互作用の検出方法 Download PDFInfo
- Publication number
- JP5937586B2 JP5937586B2 JP2013517458A JP2013517458A JP5937586B2 JP 5937586 B2 JP5937586 B2 JP 5937586B2 JP 2013517458 A JP2013517458 A JP 2013517458A JP 2013517458 A JP2013517458 A JP 2013517458A JP 5937586 B2 JP5937586 B2 JP 5937586B2
- Authority
- JP
- Japan
- Prior art keywords
- particles
- substance
- solution
- interaction
- magnetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 106
- 230000009878 intermolecular interaction Effects 0.000 title description 15
- 239000002245 particle Substances 0.000 claims description 148
- 239000000126 substance Substances 0.000 claims description 126
- 230000003993 interaction Effects 0.000 claims description 60
- 230000005291 magnetic effect Effects 0.000 claims description 43
- 230000005672 electromagnetic field Effects 0.000 claims description 25
- 230000033001 locomotion Effects 0.000 claims description 20
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000005684 electric field Effects 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 8
- -1 antibodies Proteins 0.000 claims description 7
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 5
- 210000004379 membrane Anatomy 0.000 claims description 3
- 230000001133 acceleration Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 83
- 239000000463 material Substances 0.000 description 21
- 238000001514 detection method Methods 0.000 description 19
- 210000003743 erythrocyte Anatomy 0.000 description 19
- 230000005415 magnetization Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 241000194017 Streptococcus Species 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 230000005298 paramagnetic effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000186359 Mycobacterium Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 4
- 108091000054 Prion Proteins 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000006249 magnetic particle Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001316595 Acris Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000004257 Potassium Channel Human genes 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000009582 blood typing Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002917 insecticide Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 108020001213 potassium channel Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000008175 FSH Receptors Human genes 0.000 description 2
- 108010060374 FSH Receptors Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 241000606860 Pasteurella Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229950009829 prasterone sulfate Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- WFLOTYSKFUPZQB-UHFFFAOYSA-N 1,2-difluoroethene Chemical group FC=CF WFLOTYSKFUPZQB-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000908522 Borreliella Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 241000551547 Dione <red algae> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000194030 Enterococcus gallinarum Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241001621835 Frateuria aurantia Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010035289 Glucose Dehydrogenases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 102100021489 Histone H4-like protein type G Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 108010090758 L-gulonolactone oxidase Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000236488 Lepra Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241000286819 Malo Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202952 Mycoplasma fermentans Species 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193987 Streptococcus sobrinus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- NXQOQNROJJFYCJ-FZFXZXLVSA-N androst-16-ene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC21 NXQOQNROJJFYCJ-FZFXZXLVSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002283 diesel fuel Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000003502 gasoline Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
- G01N11/10—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measurement Of Length, Angles, Or The Like Using Electric Or Magnetic Means (AREA)
Description
−ある物質と親和性を持つ第1の抗体を基板に付け、
−前記検出される物質をその基板に付けられた前記第1の抗体とある時間接触させ、
−前記抗体と反応しなかった前記物質を洗い流し、
−前記表面に付けられた前記抗体に結合した前記物質を前記物質と親和性を持つ第2の抗体と接触させ、
−前記物質と反応しなかった前記抗体を洗い流し、及び
−前記基板に接合した前記第1の抗体へ結合した前記物質へ結合した前記第2の抗体の存在を検出することを含む。
(a)溶液中に、少なくとも1つの物質を導入し、かつ好ましくは、前記第1の物質と相互作用し得る少なくとも1つの第2の物質を導入し、
(b)ステップ(a)の前記溶液中に、少なくとも2つの磁気粒子又は磁化可能粒子を導入し、前記粒子が前記溶液中に浸漬される表面上に置かれ、
(c)前記粒子が動くように設計される電場、磁場又は電磁場を適用することで、前記物質の相互作用を決定するステップを含み、前記検出される物質間の相互作用は、前記表面上の前記粒子の動きが変化する際に検出される。
これらはまた、人又は動物により次の応答で生成された抗体であり得る:例えばウイルス、菌、プリオン、寄生虫、プロトゾアなどへの感染への応答、同様に、例えば癌、自己免疫疾患例えばバセドウ病、多発性硬化症などの疾患への応答、同様に、例えば農薬、毒物、殺虫剤、除草剤、アレルギー性物質への、中毒、服毒、汚染、薬物注入、摂取、吸入及び注射などへの応答、同様に、例えば骨髄などの移植、例えば腎臓、肺又は肝臓などの器官、手、足、脚部などの手足の移植への応答、さらに同様に人工器官、移植可能な部分、ペースメーカー、人工心臓又は人工股関節の移植への応答である。
有利には、前記第1及び/又は第2の物質の密度が大きいことは、前記第1及び/又は第2の物質が前記容器の底近くに存在することを可能にする。
(a’)前記第1の物質を容器の表面に付ける先行するステップ、
(a’’)前記容器内に溶液を導入するステップ、及び
(a’’’)前記第1の物質と相互作用し得る少なくとも1つの第2の物質を導入するステップを含む。
−前記溶液、
−前記少なくとも1つの粒子、及び
−相互作用可能な前記物質を含む。
この実験では、8つの平底ウェル(参照:MSW002B、 BioFilm Control、 France)の2つのストリップがそれぞれSwH及びSwEとされ使用された。それぞれのストリップで、70μlの抗体溶液がそれぞれのウェルに入れられ、前記溶液は、15μlの、それぞれ、抗ヒトIgG抗体(参照BI2018、 Paris Anticorps、 France)又は抗Ecoli抗体(参照BP2298、 Acris Antibodies、 Germany)のいずれかを、1.5mlのPBS(8 g/lのNaCl(Sigma Aldrich、 USA)、200 mg/lのKCl (Sigma Aldrich、 USA)、1.44g/lのNa2HPO4 (Sigma Aldrich、 USA)、240mg/lのKH2PO4 (Sigma Aldrich、 USA))中で混合して得られたものであり、その後それらを16時間、37℃で安定化させた恒温装置(参照BC240、 Firelabo、 France)中に置いた。
200μlの、ヒト抗FY1抗赤血球細胞抗体を見出すための試薬(IJB−IH Control 3、参照108030357、 Institut Jacques Boy、 France)、2μlの常磁性ミクロビーズ(Ton004N、 BiofilmControl、 France)を含有し、さらに、それぞれ、15μlの注入水又は200μlの抗ヒトIgG抗体(参照BI2018、 Paris Anticorps、 France)又は200μlの抗Ecoli抗体(Reference BP2298、 Acris Antibodies GmbH、 Germany)を含む、それぞれSIg0、SIgH及びSIgEと名付けた溶液を調製した。
この実施例では、3つのストリップで、8つのSBS平坦底ウェルを持つもの(参照MSW002B、 BioFilm Control、 France)、を使用し、それぞれをSwA、SwB及びSwABと指定した。前記ストリップのそれぞれのウェルには、70μlの抗体溶液、それぞれ抗A(参照102010153、 Institut Jacques Boy、 France)、抗B(102010253、 Institut Jacques Boy、 France)、及び抗AB(参照102010353、 Institut Jacques Boy、 France)を入れた。
この実施例では、2つのストリップの8つの平坦底ウェル(参照:MSW002B、 BioFilm Control、 France)が使用された。前記ストリップのそれぞれのウェルに、1.5mlのTS緩衝液(8g/lのNaCl(Sigma Aldrich、 USA)及び1g/lのトリプトン(Difco、 USA))中に15μlの抗ヒトIgG抗体(参照BI2018、 Paris Anticorps、 France)を混合して得られる溶液の50μlを入れた。前記ストリップをその後37℃で安定化された高温装置(参照BC240、 Firelabo、 France)に16時間置いた。
−ウェルF、G及びHのリングと同程度のリングであって、前記ウェルの底部に結合された抗体と赤血球細胞との間の親和結合の不存在による顕著な移動性を示しているか、又は
−拡散したスポットであって、前記ウェルの底部に結合された抗体と赤血球細胞との間の親和結合による前記常磁性ビーズの低減された移動性を示す。
リング及びスポットが、以下表5に示される:
この実施例では、8つの平坦底部ウェルを持つ2つのストリップ(参照:MSW002B、 BioFilm Control、 France)を用いて行い、それぞれSwH及びSwEと指示する。それぞれのストリップで、それぞれのウェルに、それぞれ抗ヒトIgG抗体(参照BI2018、 Paris Anticorps、 France)及び抗Ecoli抗体(参照BP2298、 Acris Antibodies、 Germany)を、1.5mlのPBS(8g/lのNaCl(Sigma Aldrich、 USA)、200mg/lのKCl(Sigma Aldrich、 USA)、1.44g/lのNa2HPO4(Sigma Aldrich、 USA)、 240mg/lのKH2PO4(Sigma Aldrich、 USA))に混合して得られる抗体溶液を入れ、その後それらを37℃で安定化させた高温装置(参照BC240、 Firelabo、 France)に16時間置いた(表6)。
参考文献
1.US 3635678 CLOT−TIMING SYSTEM AND METHOD、 Seitz、 L.J. and Bowen、 J.G.;
2.WO 01/86255、 METHOD AND APPARATUS FOR DETERMINING LOCAL VISCOELASTICITY、 Cronin−Golomb、 M. Shabtai、 Y. Nemet、 B.;
3.EP1544596、 Method and device for determining viscosity、 Kurowski D.; Schoen C.; Peters R.; Bartos H.; Yu Y.;
4.Catterall WA. (2000) Structure and regulation of voltage−gated Ca2+ channels. Annu. Rev. Cell. Dev. Biol. 16:521−55;
5.Gerald Karp、 Biologie cellulaire et moleculaire、 Concepts et experiences [Molecular and Cellular Biology、 Concepts and Experiments]、 2nd edition 2004:
6.Dick GM and Tune JD、 Role of potassium channels in coronary vasodilation、 Exp Biol Med (Maywood). 2010 Jan;235(1):10−22;
7.Mostallino MC et al. Plasticity and function of extrasynaptic GABA(A) receptors during pregnancy and after delivery、 Psychoneuroendocrinology. 2009 Dec; 34 Suppl 1:S74−83.
Claims (12)
- 溶液中の相互作用を検出するための方法であって、
(a)溶液中に、少なくとも1つの第1の物質と、前記第1の物質と相互作用し得る少なくとも1つの第2の物質とを導入するステップ、
(b)ステップ(a)で得られる溶液中に、少なくとも2つの磁気又は磁化可能粒子を導入するステップであり、前記粒子が前記溶液内に浸漬される容器の表面上に存在する、ステップ、
(c)前記粒子が動くように設定される電場、磁場又は電磁場の適用により前記物質間の相互作用を決定するステップであり、前記物質間の相互作用が、前記粒子によって形成されたリングの直径を測定することによって決定される、ステップ、
を含む方法。 - 請求項1に記載の方法であり、前記少なくとも2つの磁気又は磁化可能粒子が、独立して、電荷を帯びた、磁気若しくは磁化可能粒子、又は少なくとも1つの磁気又は磁化可能層でカバーされている粒子である、方法。
- 請求項1又は2のいずれか一項に記載の方法であり、前記少なくとも2つの粒子が、パルス化電磁場にさらされる、方法。
- 請求項1乃至3のいずれか一項に記載の方法であり、前記粒子の移動の加速が、前記電場、磁場又は電磁場の影響下で達成される、方法。
- 請求項1乃至3のいずれか一項に記載の方法であり、前記粒子の移動の減速が、前記電場、磁場又は電磁場の影響下で達成される、方法。
- 請求項1乃至3のいずれか一項に記載の方法であり、前記粒子の軌道の変化が、前記電場、磁場又は電磁場の影響下で達成される、方法。
- 請求項1乃至3のいずれか一項に記載の方法であり、前記相互作用が、前記電場、磁場又は電磁場の影響下での前記粒子のクラスタ化により形成されたリングの直径を測定することによって決定される、方法。
- 請求項1乃至7のいずれか一項に記載の方法であり、前記少なくとも2つの粒子が、動きを検出するために光源によって照射される、方法。
- 請求項1乃至8のいずれか一項に記載の方法であり、前記少なくとも2つの粒子が、シグナル生成粒子である、方法。
- 請求項1乃至9のいずれか一項に記載の方法であり、前記第1の物質が、真核細胞、原核細胞、膜、ウイルス、タンパク質、抗体、抗原、化学分子を含む群から選択される、方法。
- 請求項1乃至9のいずれか一項に記載の方法であり、前記第2の物質が、真核細胞、原核細胞、膜、ウイルス、タンパク質、抗体、抗原、化学分子を含む群から選択される、方法。
- 請求項1乃至11のいずれか一項に記載の方法であり、ステップ(a)の代わりに、先行の
(a’)前記第1の物質を容器の表面に付けるステップ、
(a’’)前記容器に溶液を導入するステップ、及び
(a’’’)前記第1の物質と相互作用し得る少なくとも1つの第2の物質を導入するステップ、
を含む方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1002810 | 2010-07-02 | ||
FR1002810A FR2962221A1 (fr) | 2010-07-02 | 2010-07-02 | Procede de detection d'interactions moleculaires |
FR1056678A FR2962222B1 (fr) | 2010-07-02 | 2010-08-19 | Procede de detection d'interactions moleculaires |
FR1056678 | 2010-08-19 | ||
PCT/FR2011/051528 WO2012001312A1 (fr) | 2010-07-02 | 2011-06-30 | Procede de detection d'interactions moleculaires |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013530404A JP2013530404A (ja) | 2013-07-25 |
JP2013530404A5 JP2013530404A5 (ja) | 2014-08-14 |
JP5937586B2 true JP5937586B2 (ja) | 2016-06-22 |
Family
ID=43927628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013517458A Expired - Fee Related JP5937586B2 (ja) | 2010-07-02 | 2011-06-30 | 分子間相互作用の検出方法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9746407B2 (ja) |
EP (1) | EP2588845B1 (ja) |
JP (1) | JP5937586B2 (ja) |
KR (1) | KR20140002597A (ja) |
CN (1) | CN103069264B (ja) |
AP (1) | AP3750A (ja) |
AU (1) | AU2011273229B2 (ja) |
BR (1) | BR112012033591B1 (ja) |
CA (1) | CA2803743C (ja) |
EA (1) | EA028391B1 (ja) |
ES (1) | ES2585394T3 (ja) |
FR (2) | FR2962221A1 (ja) |
IL (1) | IL223809A (ja) |
MA (1) | MA34341B1 (ja) |
MX (1) | MX2013000142A (ja) |
NZ (1) | NZ605706A (ja) |
WO (1) | WO2012001312A1 (ja) |
ZA (1) | ZA201300043B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE112008001301T5 (de) | 2007-05-14 | 2010-04-29 | Reserach Foundation Of State University Of New York | Induktion einer physiologischen Dispersions-Antwort in Bakterien-Zellen in einem Biofilm |
WO2012133615A1 (ja) * | 2011-03-31 | 2012-10-04 | 積水メディカル株式会社 | 検体不添加サンプルを操作不適サンプルと判定できるイムノクロマトグラフィーに基づく検出方法及びこれに用いるテストストリップ |
WO2014155020A1 (fr) * | 2013-03-28 | 2014-10-02 | Biofilm Control | Antibiogramme rapide |
FR3020815B1 (fr) * | 2014-05-07 | 2018-09-14 | Biofilm Control | Procede de determination de l'activite enzymatique d'une enzyme et dispositif pour sa mise en œuvre |
FR3030048B1 (fr) * | 2014-12-15 | 2016-12-23 | Immunodiagnostic Systems France | Procede et dispositif de determination du temps de coagulation d’un echantillon sanguin, et cuvette de reaction |
FR3046797A1 (fr) * | 2016-01-15 | 2017-07-21 | Biofilm Control | Procede de detection rapide de sensibilite de microorganismes aux drogues |
FR3046795A1 (fr) * | 2016-01-15 | 2017-07-21 | Biofilm Control | Procede de classification de microorganismes |
US10806942B2 (en) | 2016-11-10 | 2020-10-20 | Qoravita LLC | System and method for applying a low frequency magnetic field to biological tissues |
CA3136986A1 (en) | 2019-05-06 | 2020-11-12 | Kamran Ansari | Therapeutic arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing |
US11020603B2 (en) | 2019-05-06 | 2021-06-01 | Kamran Ansari | Systems and methods of modulating electrical impulses in an animal brain using arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing |
GB202003827D0 (en) * | 2020-03-17 | 2020-04-29 | Applied Biotect Ltd | Mircofludic device and method |
CN116593356B (zh) * | 2023-06-05 | 2023-11-17 | 南京工业大学 | 一种利用磁纳米毛刷搅拌检测微量溶液粘度的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635678A (en) | 1969-06-13 | 1972-01-18 | Baxter Laboratories Inc | Clot-timing system and method |
US4935147A (en) * | 1985-12-20 | 1990-06-19 | Syntex (U.S.A.) Inc. | Particle separation method |
JPH06209794A (ja) * | 1993-01-19 | 1994-08-02 | Tokuyama Soda Co Ltd | フィブリノゲンの定量方法 |
US5443959A (en) | 1992-09-09 | 1995-08-22 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
JPH0894619A (ja) * | 1994-09-21 | 1996-04-12 | Tokuyama Corp | 免疫学的凝集反応試薬及びこれを用いた免疫学的定量方法 |
AU2001259603A1 (en) | 2000-05-08 | 2001-11-20 | Trustees Of Tufts College | Method and apparatus for determining local viscoelasticity |
EP1544596B1 (de) | 2003-12-17 | 2016-11-23 | Boehringer Ingelheim microParts GmbH | Verfahren und Vorrichtung zur Bestimmung der Viskosität |
FR2866707A1 (fr) * | 2004-02-23 | 2005-08-26 | Thierry Bernardi | Procede et dispositif permettant de detecter la formation et le developpement de biofilms dans un milieu de culture |
FR2866706B1 (fr) * | 2004-02-23 | 2014-04-18 | Thierry Bernardi | Procede et dispositif permettant de detecter la formation et le developpement de biofilms dans un milieu de culture |
FR2883296B1 (fr) * | 2005-03-15 | 2007-05-18 | Nicolas Bara | Procede et dispositif permettant d'isoler les microorganismes |
WO2008102218A1 (en) * | 2007-02-23 | 2008-08-28 | Koninklijke Philips Electronics N.V. | A sensor device for and a method of sensing magnetic particles |
JP2009069070A (ja) * | 2007-09-14 | 2009-04-02 | Olympus Corp | 標的物質の検出方法及び検出用キット |
WO2009083856A2 (en) * | 2007-12-20 | 2009-07-09 | Koninklijke Philips Electronics N.V. | Concentrated unbound magnetic particle assay for biosensors |
-
2010
- 2010-07-02 FR FR1002810A patent/FR2962221A1/fr active Pending
- 2010-08-19 FR FR1056678A patent/FR2962222B1/fr active Active
-
2011
- 2011-06-30 EP EP11743272.4A patent/EP2588845B1/fr active Active
- 2011-06-30 ES ES11743272.4T patent/ES2585394T3/es active Active
- 2011-06-30 US US13/808,077 patent/US9746407B2/en active Active
- 2011-06-30 EA EA201291396A patent/EA028391B1/ru not_active IP Right Cessation
- 2011-06-30 KR KR1020137002866A patent/KR20140002597A/ko not_active Application Discontinuation
- 2011-06-30 WO PCT/FR2011/051528 patent/WO2012001312A1/fr active Application Filing
- 2011-06-30 CN CN201180039692.5A patent/CN103069264B/zh not_active Expired - Fee Related
- 2011-06-30 JP JP2013517458A patent/JP5937586B2/ja not_active Expired - Fee Related
- 2011-06-30 MA MA35503A patent/MA34341B1/fr unknown
- 2011-06-30 AU AU2011273229A patent/AU2011273229B2/en not_active Ceased
- 2011-06-30 BR BR112012033591A patent/BR112012033591B1/pt not_active IP Right Cessation
- 2011-06-30 CA CA2803743A patent/CA2803743C/fr active Active
- 2011-06-30 AP AP2013006701A patent/AP3750A/en active
- 2011-06-30 MX MX2013000142A patent/MX2013000142A/es active IP Right Grant
- 2011-06-30 NZ NZ605706A patent/NZ605706A/en not_active IP Right Cessation
-
2012
- 2012-12-23 IL IL223809A patent/IL223809A/en active IP Right Grant
-
2013
- 2013-01-02 ZA ZA2013/00043A patent/ZA201300043B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2012001312A1 (fr) | 2012-01-05 |
US20130164736A1 (en) | 2013-06-27 |
AP2013006701A0 (en) | 2013-01-31 |
CA2803743A1 (fr) | 2012-01-05 |
BR112012033591A2 (pt) | 2016-11-29 |
CN103069264B (zh) | 2016-11-02 |
AP3750A (en) | 2016-07-31 |
CN103069264A (zh) | 2013-04-24 |
BR112012033591B1 (pt) | 2020-04-14 |
JP2013530404A (ja) | 2013-07-25 |
EP2588845A1 (fr) | 2013-05-08 |
MX2013000142A (es) | 2013-06-05 |
KR20140002597A (ko) | 2014-01-08 |
NZ605706A (en) | 2014-07-25 |
ES2585394T3 (es) | 2016-10-05 |
AU2011273229A1 (en) | 2013-01-31 |
US9746407B2 (en) | 2017-08-29 |
AU2011273229B2 (en) | 2014-09-18 |
EP2588845B1 (fr) | 2016-05-04 |
FR2962221A1 (fr) | 2012-01-06 |
FR2962222A1 (fr) | 2012-01-06 |
EA028391B1 (ru) | 2017-11-30 |
IL223809A (en) | 2017-03-30 |
CA2803743C (fr) | 2018-04-03 |
EA201291396A1 (ru) | 2013-04-30 |
ZA201300043B (en) | 2013-09-25 |
FR2962222B1 (fr) | 2018-03-30 |
MA34341B1 (fr) | 2013-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5937586B2 (ja) | 分子間相互作用の検出方法 | |
US6764860B2 (en) | Ultrasonic force differentiation assay | |
Nash et al. | Multiplexed enrichment and detection of malarial biomarkers using a stimuli-responsive iron oxide and gold nanoparticle reagent system | |
RU2530718C2 (ru) | Устройство и способы детектирования аналитов в слюне | |
Morozov et al. | Active bead-linked immunoassay on protein microarrays | |
US20090325258A1 (en) | Magnetic particle holding carrier and method for preparing the same | |
WO2008156688A2 (en) | Nonlinear magnetophoretic separation of biological substances | |
JP2000510687A (ja) | リンパ球機能の測定方法 | |
TWI757328B (zh) | 使用以相異方式將抗原固定化之承載抗原不溶性承載粒子之抗體測定法、抗體測定用試劑 | |
CN107589254B (zh) | 一种免疫脂质体复合物纳米粒子生物芯片的制造方法及应用 | |
MOLDAY | Cell Labeling and Separation Using Immunospecific Miscrospheres | |
CN201673155U (zh) | 微通道芯片检测装置 | |
EP1497652B1 (en) | Method, system and kit for detecting an analyte in a sample | |
US20100035285A1 (en) | Rapid elisa | |
US20230194527A1 (en) | A Method For Virus and Biomarker Detection | |
JPH0750112B2 (ja) | レーザ磁気免疫測定方法を実施するための検体調整方法 | |
WO2022246217A1 (en) | High volume flow-through antigen detection system | |
JPH08110341A (ja) | 免疫測定法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140624 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140624 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150616 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160328 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160404 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160426 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160512 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5937586 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |